May 30, 2025 02:46 PM EDT

AstraZeneca agrees to pay $51M to settle ‘pay-for-delay’ class action suit

Nicole DeFeudis

Editor

AstraZeneca and Handa Pharmaceuticals have agreed to pay a combined $51.4 million to resolve a class action lawsuit that claimed they unlawfully delayed the availability …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AstraZeneca agrees to pay $51M to settle ‘pay-for-delay’ class action suit

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

From weeks to days: how Aizon Intelligent Agents transform pharma validation

As­traZeneca agrees to pay $51M to set­tle ‘pay-for-de­lay’ class ac­tion suit

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca agrees to pay $51M to settle ‘pay-for-delay’ class action suit